Analysts Offer Predictions for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued to investors on Monday, February 3rd. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($4.83) for the year. HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.10) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

A number of other research analysts have also recently weighed in on CRSP. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Chardan Capital reissued a “buy” rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Barclays cut their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $77.59.

CRISPR Therapeutics Trading Up 1.2 %

Shares of CRISPR Therapeutics stock opened at $40.49 on Wednesday. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The stock has a market capitalization of $3.46 billion, a P/E ratio of -14.31 and a beta of 1.67. The business’s fifty day moving average price is $43.37 and its 200 day moving average price is $46.85.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the firm earned ($1.41) earnings per share.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. Bank of Montreal Can boosted its stake in CRISPR Therapeutics by 26.3% in the second quarter. Bank of Montreal Can now owns 7,556 shares of the company’s stock valued at $408,000 after acquiring an additional 1,574 shares during the period. Creative Planning boosted its position in shares of CRISPR Therapeutics by 3.2% during the second quarter. Creative Planning now owns 14,750 shares of the company’s stock worth $797,000 after buying an additional 456 shares during the period. Northwestern Mutual Wealth Management Co. boosted its position in shares of CRISPR Therapeutics by 4.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after buying an additional 211 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of CRISPR Therapeutics during the second quarter worth approximately $381,000. Finally, Exchange Traded Concepts LLC boosted its position in shares of CRISPR Therapeutics by 22.8% during the third quarter. Exchange Traded Concepts LLC now owns 19,192 shares of the company’s stock worth $902,000 after buying an additional 3,563 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.